Effect of Cediranib, Temozolamide and Radiotherapy in U87 GBM wtEGFR and EGFRvIII-expressing Xenografts

Authors

P. Wachsberger, Thomas Jefferson University HospitalsFollow
R. Y, Lawrence, Thomas Jefferson University Hospitals
Y. Liu, Thomas Jefferson University Hospitals
B. Andersen, Thomas Jefferson University HospitalsFollow
A. P. Dicker, Thomas Jefferson University HospitalsFollow

Abstract

Introduction: Glioblastomas (GBM) frequently overexpress the epidermal growth factor receptor (wtEGFR) or its mutant, EGFRvIII contributing to radioresistance. New treatment strategies for GBM include blockade of EGFR signaling and angiogenesis. Cediranib (CD) is a highly potent VEGFR-2 RTKI that inhibits all three VEGF receptors. This study investigated the radiosensitizing potential of CD in combination with temozolamide (TMZ) in U87 GBM xenografts expressing wtEGFR or EGFRvIII.

Radiation Research Society (RRS) 8th Annual Meeting September 25-29, Maui, HI

Recommended Citation

Wachsberger, P.; Lawrence, R. Y,; Liu, Y.; Andersen, B.; and Dicker, A. P. (2010) "Effect of Cediranib, Temozolamide and Radiotherapy in U87 GBM wtEGFR and EGFRvIII-expressing Xenografts," Bodine Journal: Vol. 3: Iss. 1, Article 21.
DOI: https://doi.org/10.29046/TBJ.003.1.020
Available at: https://jdc.jefferson.edu/bodinejournal/vol3/iss1/21